JAK1 and viral infectious disease: Immunosuppression with glucocorticoids, hydroxychloroquine, mycophenolate mofetil, and the JAK1/2 inhibitor ruxolitinib was started with good response (resolution of fever, hematological and skin manifestations), but ruxolitinib was subsequently withdrawn due to recurrent viral infection.